Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
NRG Oncology
University of California, San Francisco
M.D. Anderson Cancer Center
University of Utah
University of California, San Francisco
OHSU Knight Cancer Institute
Oxford University Hospitals NHS Trust
University of Florida
University of Washington
University of California, San Francisco
Abramson Cancer Center at Penn Medicine
Indiana University
University of California, San Francisco
University of Wisconsin, Madison
University of California, San Francisco
Indiana University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Stanford University
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Vanderbilt-Ingram Cancer Center
AstraZeneca
M.D. Anderson Cancer Center